Treating Alzheimer's and Dementia With D-ribose

Dementia Clinical Trial

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02260141
• Other study ID #: PAN- ALZ001
• Status: Terminated
• Phase: N/A
• Start date: September 2014
• Est. completion date: October 2017

Study information

• Verified date: October 2017
• Source: Practitioners Alliance Network
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To study the effectiveness of d-ribose in treating Alzheimer's and Dementia

Description:

Clinical experience and the pathophysiology of Alzheimer's, including neuronal insulin resistance, suggests that ribose improves clinical outcomes. This study will add ribose 5 gm 3 X day for 8 weeks to monitor outcomes in a pilot study.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 3
• Est. completion date: October 2017
• Est. primary completion date: October 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• A diagnosis of Alzheimer's and/or dementia with a Mini Mental Status Exam ( MMSE) score over 12 or being ambulatory and able to travel outside the home with assistance.

• Must have a caregiver living with them.

Exclusion Criteria:

• Overt and severe causes of secondary dementia such as metastatic brain cancers, or severe overt infectious encephalopathies or severe autoimmune illness.

• Also, severe life threatening illnesses which would make them unlikely to be alive after 6-12 months.

Related Conditions & MeSH terms

• Alzheimers
• Dementia

Intervention

Dietary Supplement:
• d-ribose
giving ribose in those with a diagnosis of Alzheimer's and/or dementia

Locations

Country	Name	City	State
United States	PAN	Kailua	Hawaii

Sponsors (1)

Lead Sponsor	Collaborator
Practitioners Alliance Network

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ADAS-ADL		2 months